Synlogic Reports First Quarter Financial Results and Provides Business Update
- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts -
- $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension to 2H 2023 -
- Management to host conference call and webcast at 8:30 a.m. ET today -
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs.
May 28
Individuals and organizations are encouraged to participate in the week by using the hashtags #PHGW and #PublicHealthGenetics across their social media platforms.
The following events will also occur throughout the week:
Ken Burns Presents The Gene: An Intimate History
Virtual Screening
In collaboration with WETA Washington, D.C., virtual daily screenings of
Ken Burns Presents The Gene: An Intimate History ( THE GENE ) will be held to celebrate Public Health Genetics Week. The landmark four-hour documentary series weaves together science, history, and personal stories to present a historical biography of the human genome, while also exploring groundbreaking breakthroughs for diagnosis and treatment of genetic diseases, and the complex web of moral, ethical and scientific questions raised by developments in genetics.
Chadron State Alum to present Commencement Address for Graduation Ceremony newschannelnebraska.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newschannelnebraska.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAN FRANCISCO, May 4, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021. We had a very strong start to the year, experiencing record daily volumes, and we expect that momentum to continue into the coming years, said Sean George, co-founder and chief executive officer of Invitae. Genetic information is the foundation for personalized medicine, and we believe Invitae is uniquely positioned to deliver that information from a single platform across all stages of life, ushering personalized medicine into the mainstream to improve healthcare for all.